Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: Analysis of patients beginning adjunctive treatment in a 52-week, open-label study

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Clayton, Anita H ^a   Baker, Ross A ^b   Sheehan, John J ^c   Cain, Zachary J ^c   Forbes, Robert A ^b   Marler, Sabrina Vogel ^c   Marcus, Ronald ^c   Berman, Robert M ^c   Thase, Michael E ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjunctive antidepressant; Aripiprazole; Atypical antipsychotic; Bupropion; Dopamine; Major depressive disorder; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors; Sexual dysfunction

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; NORADRENALIN; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PIPERAZINES; QUINOLONES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84904276190     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-459     Document Type: Article

References (26)

1. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB, J Pharmacol Exp Ther 2002 302 381 389
2. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R, Neuropsychopharmacol 2003 28 1400 1411
3. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA, Eur J Pharmacol 2004 483 45 53
4. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA, Eur J Pharmacol 2002 441 137 140
5. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Tadori Y, Forbes RA, McQuade RD, Kikuchi T, Eur J Pharmacol 2008 597 27 33
6. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A, J Clin Psychiatry 2007 68 843 853
7. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM, J Clin Psychopharmacol 2008 28 156 165
8. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. Berman R, Fava M, Thase M, Swanink R, McQuade R, Carson W, Adson D, Taylor L, Hazel J, Marcus R, CNS Spectrums 2009 14 197 206
9. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN, Neuropsychiatr Dis Treat 2011 7 303 312
10. - 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA, Prim Care Companion J Clin Psychiatry 2005 7 106 113
11. American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder American Psychiatric Publishing: Third edition 2010
12. Major depressive disorder, antidepressants, and sexual dysfunction. Clayton AH, Montejo AL, J Clin Psychiatry 2006 67 Suppl 6 33 37
13. Recognition and assessment of sexual dysfunction associated with depression. Clayton AH, J Clin Psychiatry 2001 62 Suppl 3 5 9
14. Spotlight on bupropion in major depressive disorder. Dhillon S, Yang LP, Curran MP, CNS Drugs 2008 22 613 617
15. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y, J Clin Psychiatry 2005 66 974 981
16. Prevalence of sexual dysfunction among newer antidepressants. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A, J Clin Psychiatry 2002 63 357 366
17. The efficacy, tolerability, and safety of contemporary antidepressants. Papakostas GI, J Clin Psychiatry 2010 71 Suppl E1 03
18. The hidden third: improving outcome in treatment-resistant depression. Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S, J Psychopharmacol 2012 26 587 602
19. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P, Psychol Med 2012 42 967 980
20. Adjunctive antipsychotics for major depression. Med Lett Drugs Ther 2011 53 74 75
21. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ, Psychiatr Clin North Am 2003 26 457 494 x
22. Clinical Global Impressions (CGI). Guy W, ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76-338 Rockville, MD: National Institute of Mental Health 1976 218 222
23. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Labbate LA, Lare SB, Psychother Psychosom 2001 70 221 225
24. Debate: Subgroup analyses in clinical trials: fun to look at-but don't believe them! Sleight P, Curr Control Trials Cardiovasc Med 2000 1 25 27
25. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM, Prim Care Companion CNS Disord 2011 13 1 CC.10m00994
26. Adjunctive aripiprazole for bupropion-resistant major depression. Sokolski KN, Ann Pharmacother 2008 42 1124 1129